The Food and Drug Administration has greenlighted clinical trials for transplantation of gene-edited pig kidneys into humans, marking a major milestone in xenotransplantation research. These trials aim to address organ shortages by using organs from genetically modified pigs engineered to reduce rejection risks. This regulatory progression reflects growing confidence in the safety and efficacy of xenogeneic organ transplants, potentially transforming end-stage organ failure treatment paradigms globally.